The Fabp5/calnexin complex is a prerequisite for sensitization of mice to experimental autoimmune encephalomyelitis.
Animals
Biological Transport
/ physiology
Blood-Brain Barrier
/ metabolism
Brain
/ metabolism
Calnexin
/ metabolism
Cell Line
Cell Movement
/ physiology
Disease Models, Animal
Encephalomyelitis, Autoimmune, Experimental
/ metabolism
Endothelial Cells
/ metabolism
Fatty Acid-Binding Proteins
/ metabolism
Female
Humans
Male
Mice
Mice, Inbred C57BL
Mice, Transgenic
Neoplasm Proteins
/ metabolism
Permeability
blood brain barrier
calnexin
chaperone
fatty acid binding protein
multiple sclerosis
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
16
06
2020
revised:
01
10
2020
accepted:
13
10
2020
pubmed:
31
10
2020
medline:
23
4
2021
entrez:
30
10
2020
Statut:
ppublish
Résumé
We previously showed that calnexin (Canx)-deficient mice are desensitized to experimental autoimmune encephalomyelitis (EAE) induction, a model that is frequently used to study inflammatory demyelinating diseases, due to increased resistance of the blood-brain barrier to immune cell transmigration. We also discovered that Fabp5, an abundant cytoplasmic lipid-binding protein found in brain endothelial cells, makes protein-protein contact with the cytoplasmic C-tail domain of Canx. Remarkably, both Canx-deficient and Fabp5-deficient mice commonly manifest resistance to EAE induction. Here, we evaluated the importance of Fabp5/Canx interactions on EAE pathogenesis and on the patency of a model blood-brain barrier to T-cell transcellular migration. The results demonstrate that formation of a complex comprised of Fabp5 and the C-tail domain of Canx dictates the permeability of the model blood-brain barrier to immune cells and is also a prerequisite for EAE pathogenesis.
Identifiants
pubmed: 33124722
doi: 10.1096/fj.202001539RR
doi:
Substances chimiques
Canx protein, mouse
0
Fabp5 protein, mouse
0
Fatty Acid-Binding Proteins
0
Neoplasm Proteins
0
Calnexin
139873-08-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16662-16675Subventions
Organisme : CIHR
ID : MOP-15291
Pays : Canada
Organisme : CIHR
ID : MOP-15415
Pays : Canada
Organisme : CIHR
ID : PS-153325
Pays : Canada
Organisme : CIHR
ID : MOP-86750
Pays : Canada
Organisme : CIHR
ID : PS 168843
Pays : Canada
Informations de copyright
© 2020 Federation of American Societies for Experimental Biology.
Références
Haunerland NH, Spener F. Fatty acid-binding proteins-insights from genetic manipulations. Prog Lipid Res. 2004;43:328-349.
Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008;7:489-503.
Richieri GV, Ogata RT, Zimmerman AW, Veerkamp JH, Kleinfeld AM. Fatty acid binding proteins from different tissues show distinct patterns of fatty acid interactions. Biochemistry. 2000;39:7197-7204.
Zimmerman AW, van Moerkerk HT, Veerkamp JH. Ligand specificity and conformational stability of human fatty acid-binding proteins. Int J Biochem Cell Biol. 2001;33:865-876.
Ockner RK, Manning JA, Poppenhausen RB, Ho WK. A binding protein for fatty acids in cytosol of intestinal mucosa, liver, myocardium, and other tissues. Science. 1972;177:56-58.
Madsen P, Rasmussen HH, Leffers H, Honore B, Celis JE. Molecular cloning and expression of a novel keratinocyte protein (psoriasis-associated fatty acid-binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and that shares similarity to fatty acid-binding proteins. J Invest Dermatol. 1992;99:299-305.
Owada Y. Fatty acid binding protein: localization and functional significance in the brain. Tohoku J Exp Med. 2008;214:213-220.
Owada Y, Suzuki I, Noda T, Kondo H. Analysis on the phenotype of E-FABP-gene knockout mice. Mol Cell Biochem. 2002;239:83-86.
Constantinescu CS, Farooqi N, O'Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 2011;164:1079-1106.
't Hart BA. Experimental autoimmune encephalomyelitis in the common marmoset: a translationally relevant model for the cause and course of multiple sclerosis. Primate Biol. 2019;6:17-58.
Bjelobaba I, Begovic-Kupresanin V, Pekovic S, Lavrnja I. Animal models of multiple sclerosis: focus on experimental autoimmune encephalomyelitis. J Neurosci Res. 2018;96:1021-1042.
Glatigny S, Bettelli E. Experimental autoimmune encephalomyelitis (EAE) as animal models of multiple sclerosis (MS). Cold Spring Harb Perspect Med. 2018;8:a028977.
Hebert DN, Molinari M. In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol Rev. 2007;87:1377-1408.
Wada I, Rindress D, Cameron PH, et al. SSR alpha and associated calnexin are major calcium binding proteins of the endoplasmic reticulum membrane. J Biol Chem. 1991;266:19599-19610.
Kraus A, Groenendyk J, Bedard K, et al. Calnexin deficiency leads to dysmyelination. J Biol Chem. 2010;285:18928-18938.
Jung J, Eggleton P, Robinson A, et al. Calnexin is necessary for T cell transmigration into the central nervous system. JCI Insight. 2018;3:e98410.
Jung J, Wang J, Groenendyk J, Lee D, Michalak M, Agellon LB. Fatty acid binding protein (Fabp) 5 interacts with the calnexin cytoplasmic domain at the endoplasmic reticulum. Biochem Biophys Res Commun. 2017;493:202-206.
Haile Y, Deng X, Ortiz-Sandoval C, et al. Rab32 connects ER stress to mitochondrial defects in multiple sclerosis. J Neuroinflammation. 2017;14:19.
Holley JE, Newcombe J, Whatmore JL, Gutowski NJ. Increased blood vessel density and endothelial cell proliferation in multiple sclerosis cerebral white matter. Neurosci Lett. 2010;470:65-70.
Stromnes IM, Goverman JM. Passive induction of experimental allergic encephalomyelitis. Nat Protoc. 2006;1:1952-1960.
Lee D, Kraus A, Prins D, et al. UBC9-dependent association between calnexin and protein tyrosine phosphatase 1B (PTP1B) at the endoplasmic reticulum. J Biol Chem. 2015;290:5725-5738.
Kodama Y, Hu CD. Bimolecular fluorescence complementation (BiFC): a 5-year update and future perspectives. Biotechniques. 2012;53:285-298.
Sikorski EE, Hallmann R, Berg EL, Butcher EC. The Peyer's patch high endothelial receptor for lymphocytes, the mucosal vascular addressin, is induced on a murine endothelial cell line by tumor necrosis factor-alpha and IL-1. J Immunol. 1993;151:5239-5250.
Watanabe T, Dohgu S, Takata F, et al. Paracellular barrier and tight junction protein expression in the immortalized brain endothelial cell lines bEND.3, bEND.5 and mouse brain endothelial cell 4. Biol Pharm Bull. 2013;36:492-495.
Rao E, Singh P, Li Y, et al. Targeting epidermal fatty acid binding protein for treatment of experimental autoimmune encephalomyelitis. BMC Immunol. 2015;16:28.
Li B, Reynolds JM, Stout RD, Bernlohr DA, Suttles J. Regulation of Th17 differentiation by epidermal fatty acid-binding protein. J Immunol. 2009;182:7625-7633.
Boord JB, Maeda K, Makowski L, et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation. 2004;110:1492-1498.
Masouye I, Hagens G, Van Kuppevelt TH, et al. Endothelial cells of the human microvasculature express epidermal fatty acid-binding protein. Circ Res. 1997;81:297-303.
Owada Y, Takano H, Yamanaka H, et al. Altered water barrier function in epidermal-type fatty acid binding protein-deficient mice. J Invest Dermatol. 2002;118:430-435.
Pan Y, Short JL, Choy KH, et al. Fatty acid-binding protein 5 at the blood-brain barrier regulates endogenous brain docosahexaenoic acid levels and cognitive function. J Neurosci. 2016;36:11755-11767.
Reynolds JM, Liu Q, Brittingham KC, et al. Deficiency of fatty acid-binding proteins in mice confers protection from development of experimental autoimmune encephalomyelitis. J Immunol. 2007;179:313-321.
Balasa R, Barcutean L, Balasa A, Motataianu A, Roman-Filip C, Manu D. The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis. Hum Immunol. 2020;81:237-243.
Engelhardt B, Vajkoczy P, Weller RO. The movers and shapers in immune privilege of the CNS. Nat Immunol. 2017;18:123-131.
Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37:13-25.
Andreone BJ, Chow BW, Tata A, et al. Blood-brain barrier permeability is regulated by lipid transport-dependent suppression of caveolae-mediated transcytosis. Neuron. 2017;94:581-594.e5.
Denzel A, Molinari M, Trigueros C, et al. Early postnatal death and motor disorders in mice congenitally deficient in calnexin expression. Mol Cell Biol. 2002;22:7398-7404.
Ghosh I, Hamilton AD, Regan L. Antiparallel leucine zipper-directed protein reassembly: application to the green fluorescent protein. J Am Chem Soc. 2000;122:5658-5659.
Miller KE, Kim Y, Huh WK, Park HO. Bimolecular fluorescence complementation (BiFC) analysis: advances and recent applications for genome-wide interaction studies. J Mol Biol. 2015;427:2039-2055.
Roderick HL, Lechleiter JD, Camacho P. Cytosolic phosphorylation of calnexin controls intracellular Ca2+ oscillations via an interaction with SERCA2b. J. Cell Biol. 2000;149:1235-1248.
Myhill N, Lynes EM, Nanji JA, et al. The subcellular distribution of calnexin is mediated by PACS-2. Mol Biol Cell. 2008;19:2777-2788.
Cameron PH, Chevet E, Pluquet O, Thomas DY, Bergeron JJ. Calnexin phosphorylation attenuates the release of partially misfolded alpha1-antitrypsin to the secretory pathway. J Biol Chem. 2009;284:34570-34579.
Lynes EM, Bui M, Yap MC, et al. Palmitoylated TMX and calnexin target to the mitochondria-associated membrane. EMBO J. 2012;31:457-470.
Lynes EM, Raturi A, Shenkman M, et al. Palmitoylation is the switch that assigns calnexin to quality control or ER calcium signaling. J Cell Sci. 2013;126:3893-3903.
Lakkaraju AK, van der Goot FG. Calnexin controls the STAT3-mediated transcriptional response to EGF. Mol Cell. 2013;51:386-396.
Li HD, Liu WX, Michalak M. Enhanced clathrin-dependent endocytosis in the absence of calnexin. PLoS ONE. 2011;6:e21678.
Hunegnaw R, Vassylyeva M, Dubrovsky L, et al. Interaction between HIV-1 Nef and Calnexin: from modeling to small molecule inhibitors reversing HIV-induced lipid accumulation. Arterioscler Thromb Vasc Biol. 2016;36:1758-1771.
Dudek E, Millott R, Liu WX, Beauchamp E, Berthiaume LG, Michalak M. N-myristoyltransferase 1 interacts with calnexin at the endoplasmic reticulum. Biochem Biophys Res Commun. 2015;468:889-893.
Myrum C, Soule J, Bittins M, et al. Arc interacts with the integral endoplasmic reticulum protein. Calnexin. Front Cell Neurosci. 2017;11:294.
Agellon LB, Michalak M. The endoplasmic reticulum and the cellular reticular network. Adv Exp Med Biol. 2017;981:61-76.
Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502-1517.
Montalban X, Tintore M, Swanton J, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology. 2010;74:427-434.
Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15:545-558.
Schrag JD, Bergeron JJ, Li Y, et al. The structure of calnexin, an ER chaperone involved in quality control of protein folding. Mol Cell. 2001;8:633-644.